Antibiotics for the treatment of hepatic encephalopathy

Metabolic Brain Disease

Volumn 28, Issue 2, 2013, Pages 307-312

  Patidar, Kavish R ^a   Bajaj, Jasmohan S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Covert hepatic encephalopathy; Economics; Metronidazole; Neomycin; Rifaximin; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; LACTULOSE; METRONIDAZOLE; NEOMYCIN; PAROMOMYCIN; PLACEBO; RIBOSTAMYCIN; RIFAMYCIN; RIFAXIMIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONSTIPATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FLATULENCE; HEPATIC ENCEPHALOPATHY; HUMAN; MALABSORPTION; MENTAL HEALTH; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; QUALITY OF LIFE; RECURRENT DISEASE; RIBOSOME SUBUNIT; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; COMPLICATION; ECONOMICS; INFECTION;

ENTEROCOCCUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; INFECTION;

EID: 84878011784     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-013-9383-5     Document Type: Conference Paper

References (46)

1. Alcorn J (2008) Review: rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy. ACP J Club 149(5):11
2. Atterbury CE, Maddrey WC, Conn HO (1978) Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial. Am J Dig Dis 23:398-406
3. Bajaj JS (2010) Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 31(5):537-547
4. Bajaj JS, Riggio O (2010) Drug therapy: rifaximin. Hepatology 52(4):1484-1488
5. Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ (2011) Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 140(2):478-487
6. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM (2012a) Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 303(6):G675-G685
7. Bajaj JS, O'Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, Brown G, Noble NA, Thacker LR, Kamath PS (2012b) Second infections independently increase mortality in hospitalized patients with cirrhosis: the north american consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 56(6):2328-2335
8. Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM (2012c) Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 55(4):1164-1171
9. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362(12):1071-1081
10. Blei AT, Cordoba J (2001) Hepatic encephalopathy. Am J Gastroenterol 96:1968-1976
11. Brigidi P, Swennen E, Rizzello F, Bozzolasco M, Matteuzzi D (2012) Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 14(3):290-295
12. Bucci L, Palmieri GC (1993) Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 13:109-118
13. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL (1977) Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 72(4 Pt 1):573-583
14. Fera G, Agostinacchio F, Nigro M, Schiraldi O, Ferrieri A (1993) Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 4(1):57-66
15. Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Ginès P, Arroyo V (2012) Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 55(5):1551-1561
16. Festi D, Mazzella G, Orsini M, Scottili S, Sangermano A, Li Bassi S, Ferrieri A, Falcucci M, Grossi L, Marzio L, Roda E (1993) Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 54(5):598-609
17. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R (2009) Severe Sepsis in cirrhosis. Hepatology 50(6):2022-2033
18. Huang E, Esrailian E, Spiegel BMR (2007) The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy: a decision analysis. Aliment Pharmacol Ther 26:1147-1161
19. Jalan R (2010) Rifaximin in hepatic encephalopathy: more than just a non-absorable antibiotic? J Hepatol 53(3):580-582
20. Jiang ZD, DuPont HL (2005) Rifaximin: in vitro and in vivo antibacterial activity-a review. Chemotherapy 51(Suppl 1):67-72
21. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Fotopoulos A, Xourgia X, Tsiansos EV (2012) Rifaximin improves systemic hemodynamics and renal function in patients with alchol-related cirrhosis and ascites. Clin Gastroenterol Hepatol 10(7):815-818
22. Leevy CB, Phillips JA (2007) Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 52:737-741
23. Loft S, Sonne J, Dossing M, Andreasen PB (1987) Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 22(1):117-123
24. Mantry PS, Munsaf S (2010) Rifaximin for the treatment of hepatic encephalopathy. Transplant Proc 42(10):4543-4547
25. Marco F, Amato PS, D'Arienzo A (1984) Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. Curr Ther Res 36:668-674
26. Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, Pardo A (2003) Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 38(1):51-58
27. Massa P, Vallerino E, Dodero M (1993) Treatment of hepatic encephalopathy with rifaximin: double-blind, double-dummy study versus lactulose. Eur J Clin Res 4:7-18
28. Morgan MH, Read AE, Speller DC (1982) Treatment of hepatic encephalopathy with metronidazole. Gut 23(1):1-7
29. Neff GW, Kemmer N, Kaiser T, Zacharias V, Majoras N, Safdar K (2007) Outcomes in adult and pediatric liver transplantation among various ethnic groups. Transplant Proc 39(10):3204-3206
30. Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N (2012) Durability of rifaximin response in hepatic encephalopathy. J Clin Gastroenterol 46(2):168-171
31. Orlandi F, Freddara U, Candelaresi MT, Morettini A, Corazza GR, Di Simone A, Dobrilla G, Cavallini G (1981) Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 26(6):498-506
32. Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, Chon CY, Lee SI, Moon YM (2005) Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 46(3):399-407
33. Parini P, Cipolla A, Ronci M, Antionio M, Salzetta A, Mazzella G, Roda E (1992) Effect of paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res 52:34
34. Poh Z, Chang PE (2012) A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol 2012:480309
35. Poordad FF (2007) Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 1:3-9
36. Prakash R, Mullen KD (2010) Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 7:515-525
37. Riggio O, Mannaioni G, Ridola L, Angeloni S, Merli M, Carlà V, Salvatori FM, Moroni F (2010) Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy. Am J Gastroenterol 105(6):1374-1381
38. Sanyal A, Bass N, Poorad F, Sheikh MY, Mullen K, Sigal S, Frederick T, Brown, Jr R, Bhandari B, Sedghi S, Merchant K, Huang S, Shaw A, Bortey E, Forbes W (2010) Rifaximin decreases venous ammonia concentrations and time-weighted average ammonia concentrations correlate with overt hepatic encephalopathy (HE) as assessed by Conn Score in a 6-months study. Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver Abstract 195
39. Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP (2011) Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther 34(8):853-861
40. Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, Auzinger G, Bernal W, Wendon JA (2011) Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 54:640-649
41. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK (2011) Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 106(2):307-316
42. Stepanova M, Mishra A, Venkatesan C, Younossi ZM (2012) In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 10(9):1034-1041
43. Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA, de Sá MF (1992) Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 39(6):542-545
44. Tarao K, Ikeda T, Hayashi K, Sakurai A, Okada T, Ito T, Karube H, Nomoto T, Mizuno T, Shindo K (1990) Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 31(6):702-706
45. Testa R, Eftimiadi C, Sukkar GS, De Leo C, Rovida S, Schito GC, Celle G (1985) Drugs Exp Clin Res 11(6):387-392
46. U.S. Food and Drug Administration (2010) Briefing Document for Gastrointestinal Drugs Advisory Committee Meeting 23 February 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM201081.pdf. Accessed 3 December 2012